Mayne Pharma Group Limited
MAYNF
$3.29
-$0.23-6.54%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 63.80% | 62.95% | -- | -- | -124.11% |
| Total Depreciation and Amortization | -11.71% | -9.65% | -- | -- | 9.21% |
| Total Amortization of Deferred Charges | 74.48% | 78.56% | -- | -- | -21.95% |
| Total Other Non-Cash Items | -194.75% | -196.96% | -- | -- | 105.57% |
| Change in Net Operating Assets | 105.62% | 105.75% | -- | -- | -139.34% |
| Cash from Operations | 54.64% | 53.58% | -- | -- | 49.90% |
| Capital Expenditure | -116.47% | -121.55% | -- | -- | 16.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -154.16% | -155.42% | -- | -- | -85.52% |
| Cash from Investing | -166.94% | -168.50% | -- | -- | -86.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 83.85% | 83.85% | -- | -- | 97.33% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -48.80% | -48.80% | -- | -- | 293.68% |
| Cash from Financing | 98.71% | 98.68% | -- | -- | 94.09% |
| Foreign Exchange rate Adjustments | 215.03% | 217.73% | -- | -- | 53.10% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -439.24% | -447.17% | -- | -- | -79.13% |